0.3651

4.40% 0.0154

Relmada Therapeutics Inc (RLMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Relmada Therapeutics Inc stock is traded at $0.3651, with a volume of 1.20M. It is up +4.40% in the last 24 hours and up +20.46% over the past month. Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Previous Close:

$0.3497

Open:

$0.3498

24h Volume:

1.20M

Relative Volume:

0.58

Market Cap:

$21.41M

Revenue:

Net Income/Loss:

$-98.79M

P/E Ratio:

-0.1117

EPS:

-3.27

Net Cash Flow:

$-51.66M

1W Performance:

-43.40%

1M Performance:

+20.46%

6M Performance:

-89.54%

1Y Performance:

-90.19%

1-Day Range:

$0.3315

$0.3841

1-Week Range:

$0.2675

$0.7409

52-Week Range:

$0.2404

$4.47

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Name

Relmada Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (677)

Phone

646 876 3459

Address

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Employee

Twitter

@relmada

Next Earnings Date

2025-03-25

Latest SEC Filings

RLMD's Discussions on Twitter

Compare RLMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLMD	3.03	0	0	0	0	0.00
GOODO Gladstone Commercial Corporation	20.23	372.90M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	0.1601	355.59M	2.07B	-1.42B	-1.37B	-0.6765
MOBBW Mobilicom Limited Warrants	0.2199	318.40M	0	0	0	0.00
JUNE Dhandho Junoon Etf	11.50	211.65M	0	0	0	0.00
SHMD Schmid Group N V	4.00	156.75M	0	0	0	0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral
Sep-17-24	Upgrade	Jefferies	Hold → Buy
Jun-05-24	Downgrade	Goldman	Neutral → Sell
Oct-14-22	Downgrade	Goldman	Buy → Neutral
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Truist	Buy → Hold
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform
Nov-18-21	Initiated	Mizuho	Buy
May-20-21	Resumed	Goldman	Buy
Oct-28-20	Downgrade	Goldman	Buy → Neutral
Jul-14-20	Initiated	Oppenheimer	Outperform
May-04-20	Initiated	SunTrust	Buy
Apr-21-20	Initiated	Goldman	Buy
Jan-27-20	Initiated	Jefferies	Buy
Jan-10-20	Initiated	SVB Leerink	Outperform
Dec-16-19	Initiated	Guggenheim	Buy

View All

Relmada Therapeutics Inc Stock (RLMD) Latest News

May 02, 2025

Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

May 02, 2025

May 01, 2025

Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com

May 01, 2025

Apr 30, 2025

It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News

Apr 30, 2025

Apr 29, 2025

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News

Apr 29, 2025

Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX

Apr 29, 2025

Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus

Apr 29, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus

Apr 29, 2025

Apr 28, 2025

Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com

Apr 28, 2025

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com

Apr 28, 2025

Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada

Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com

Apr 28, 2025

SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow

Apr 28, 2025

Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider

Apr 28, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow

Apr 28, 2025

Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan

Apr 28, 2025

Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 28, 2025

Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus

Apr 28, 2025

Apr 27, 2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus

Apr 27, 2025

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq

Apr 27, 2025

Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan

Apr 27, 2025

Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025

Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX

Apr 25, 2025

Apr 24, 2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times

Apr 24, 2025

Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan

Apr 24, 2025

Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News

Apr 24, 2025

Apr 23, 2025

RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com

Apr 23, 2025